When patients with coronary in-stent restenosis (ISR) require reintervention, should specialists turn to drug-coated balloon (DCB) angioplasty or a drug-eluting stent (DES)?

How should nonculprit lesions be evaluated? And when is the ideal time for complete revascularization?

Heart transplant (HT) recipients have an increased risk of experiencing severe complications if infected with COVID-19, according to new findings published in JAMA Cardiology.

What is the best way to determine—and improve—the quality of a PCI program?

Newer-generation drug-eluting stents (n-DES) are a more effective option for the percutaneous treatment of small-vessel coronary disease (SVCD) than drug-coated balloons (DCBs), according to new findings published in JACC: Cardiovascular Interventions.

Women are at an increased risk of adverse events following percutaneous coronary intervention (PCI), according to new findings published in the Journal of the American College of Cardiology.

Heart bypass patients experience better outcomes when the surgeon uses a segment of the radial artery instead of one from the saphenous vein, according to a new analysis of more than 1,000 patients.   

As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.

Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.

A Feb. 18 decision by the Utah Supreme Court means that more than 1,000 patients are free to pursue claims against Salt Lake City cardiologist Sherman Sorensen, who’s been accused of performing hundreds of unnecessary PFO and ASD closures.

Researchers on the EXCEL trial have been accused of withholding key mortality data when they first published results suggesting stents were as safe as open-heart surgery in treating patients with left main disease.

Philips is launching a new randomized controlled trial—dubbed DEFINE GPS—to assess patient outcomes after PCI guided by instant wave-Free Ratio measurements and angiograms.